In designing the operation, it had always intended on expanding there, adding one of the biologic products that are becoming more important to its future.
It's been a long time coming, but Bristol-Myers Squibb's ($BMY) Orencia finally won a new thumbs up from U.K. cost-effectiveness watchdogs. The difference: A new discount, size unspecified, that put the rheumatoid arthritis drug more in line with its peers.
Five years in the making and a year in testing, Bristol-Myers Squibb ($BMY) has now been given the go-ahead by the FDA to begin manufacturing at a new plant in Devens, MA.
Britain's healthcare cost watchdog NICE has recommended against using Bristol-Myers Squibb's (BMY.N) rheumatoid arthritis drug Orencia on the state health service as a second-line treatment. Report
In yet another crackdown on manufacturing violations, the FDA has cited Bristol-Myers Squibb for repeated problems at a plant in Puerto Rico. The plant makes at least eight products, including
Could a label change help Bristol-Myers Squibb give a big boost to arthritis remedy Orencia? The company hopes so. The drug's label had specified Orencia use for patients who didn't respond to
A triad of Bristol-Myers Squibb news today, some good, some not-so-good. First, let's get the earnings out of the way: The company reported a decline in earnings on restructuring charges, but
Four companies, two disputed patents, two multimillion-dollar settlements. Repligen and Bristol-Myers Squibb buried the hatchet over Orencia, the rheumatoid arthritis treatment that's been subject